One of the largest global pharmaceutical companies has chosen Labcorp as its strategic partner for statistical programming and statistical analysis services - for more than a decade. Working together, we ensure accurate, insightful clinical trial data management from the moment it's recorded to the moment it's reported.

A mid-sized, global pharmaceutical company relies on Labcorp for ongoing pharmacokinetics (PK) modeling and statistical programming support on niche projects. The key objective is to consolidate datasets from global Phase I/II studies of varying complexity.

Our endocrine system controls many basic body functions and plays a key role in reproduction and development. Disruption of this system can have profound effects on individuals, but also on whole populations and ecosystems.

Nanomaterials are chemical substances that have a particle size between 1 and 100 nanometres (nm) in at least one dimension.

Labcorp was approached by a client with a synthetic graphite nanotube used in specialized applications who needed to register it in the European Union under REACH (Registration, Evaluation, Authorization and restriction of Chemicals) regulation.

A major pharmaceutical company was running a global Phase III program and choose the Mobile Clinical Services group at Labcorp Drug Development (Labcorp) to advance their studies. They wanted to collect stool samples from their oncology patients and needed dedicated support to help educate patients on collection and shipment techniques.

Spinal cord injury (SCI) occurring in C through T2 are the most severe injuries requiring a great amount of advance planning, education and on-boarding of sites, and are performed in Level 1 Trauma Emergency Rooms (ERs) in the U.S., and the largest hospitals accepting these critical patients in ex-U.S. countries.

Labcorp has recently completed full-service execution of a Phase I multiple ascending dose (MAD) study in Parkinson's disease (PD) patients. This case study presented a typical set of challenges encountered when executing PD studies, as well as unique challenges pertaining to the specifics of the protocol.

In this case study, we outline key challenges and achievements from a recently completed Phase III study in stroke patients.

A small biopharmaceutical client was developing a higher-dose version of an existing treatment to block symptoms of opioid withdrawal. Since the drug had been on the market for some time, no current testing data were available.